More than 220,000 men are expected to be diagnosed with prostate cancer and more than 27,000 are expected to die of the disease in the United States alone in 2015 (ref. 1). Approximately 58% of risk for prostate cancer has been estimated to be due to inherited genetic factors [2] [3] [4] [5] [6] . Thus far, genome-wide association studies (GWAS) have identified more than 100 common risk variants for prostate cancer that explain ~33% of the familial risk [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , leaving the majority of risk unexplained. Because GWAS have primarily investigated common variants (MAF >1%) for association with prostate cancer risk, an unexplored hypothesis is that part of the 'missing heritability' is attributable to rare variants (MAF <1%). To address this hypothesis, we focused on examining rare variation at known susceptibility regions that are only partially tagged by GWAS arrays. The rationale for investigating known risk-associated regions is that, (i) unlike in the rest of the genome, genetic variation in these regions has been established to confer risk and (ii) there are examples of rare and low-frequency variation at known GWAS-identified risk regions being important for a number of common diseases, including prostate cancer (8q24) [26] [27] [28] [29] .
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More than 220,000 men are expected to be diagnosed with prostate cancer and more than 27,000 are expected to die of the disease in the United States alone in 2015 (ref. 1) . Approximately 58% of risk for prostate cancer has been estimated to be due to inherited genetic factors [2] [3] [4] [5] [6] . Thus far, genome-wide association studies (GWAS) have identified more than 100 common risk variants for prostate cancer that explain ~33% of the familial risk [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , leaving the majority of risk unexplained. Because GWAS have primarily investigated common variants (MAF >1%) for association with prostate cancer risk, an unexplored hypothesis is that part of the 'missing heritability' is attributable to rare variants (MAF <1%). To address this hypothesis, we focused on examining rare variation at known susceptibility regions that are only partially tagged by GWAS arrays. The rationale for investigating known risk-associated regions is that, (i) unlike in the rest of the genome, genetic variation in these regions has been established to confer risk and (ii) there are examples of rare and low-frequency variation at known GWAS-identified risk regions being important for a number of common diseases, including prostate cancer (8q24) [26] [27] [28] [29] .
We carried out targeted sequencing of known prostate cancer GWAS loci to investigate the contribution of low-frequency and rare variation to prostate cancer risk. We targeted all 63 autosomal risk regions for prostate cancer that were known to us at the time of study design (since then, an additional 37 loci have been discovered). For each region, we started with the index SNP previously associated with prostate cancer by GWAS and attempted to tile Agilent SureSelect baits to cover all nucleotides within a block of strong linkage disequilibrium (LD) around the SNP (plus exons and conserved elements within 200 kb of the SNP). We constructed individually barcoded next-generation sequencing libraries for all of the samples, pooled these into sets that typically contained 24 libraries each, and then performed in-solution hybrid enrichment. After removal of duplicated molecules, we achieved an average coverage of 9.3× in 9,237 cases and controls across four ancestry groups (4,006 African, 1,753 European, 1,770 Japanese and 1,708 Latino). We identified 197,786 variants that were present in all ancestry groups, imputed genotypes into all individuals, and then correlated the genotypes to prostate cancer risk.
First, we show that sequencing-based association analysis is able to study a substantially larger fraction of the genetic risk for prostate cancer than studies of common variants alone, as we find that the variance explained in the trait by all the sequenced variants is The contribution of rare variation to prostate cancer heritability significantly larger than the variance explained by known GWAS variants at the same loci. Second, we find evidence of genetic heterogeneity by ancestry in risk for prostate cancer. Third, we use variance-components methods to partition the SNP heritability across different variant frequency classes and find that a large amount of SNP heritability comes from the rare variant class in men of African ancestry; that is, variants with 0.1% ≤ MAF < 1% explain a point estimate of 0.12 of variance in the trait as compared to an estimate of 0.17 for variants with MAF ≥ 1%. Third, we used the SNP heritability assigned to the rare variant class to make the first relatively precise estimate of the strength of coupling between selection and allelic effect for a common trait. Finally, we replicated association signals at known GWAS loci and used an approach that combines epigenetic annotation (e.g., localization of androgen receptor binding sites in a prostate adenocarcinoma cell line) with the association signal to identify plausible causal variants at some of these loci.
RESULTS

Experimental strategy
To explore the contribution of rare and low-frequency variation to risk of prostate cancer, we targeted 90 index SNPs at 63 autosomal regions that had been associated with prostate cancer risk by GWAS at the time that this study was designed (October 2011). For each index SNP, we used Haploview 30 (HapMap release 24) to visualize the surrounding LD block in European-ancestry individuals. We then manually identified boundaries for target capture on the basis of the region where LD as measured by the absolute value of Lewontin's D′ fell precipitously (Supplementary Table 1 and Supplementary Data Set 1). We also targeted all exons (defined on the basis of RefSeq annotation) within 200 kb of each index SNP together with all conserved noncoding sequences (defined on the basis of a 29-mammal alignment 31 ) within 5 kb of each exon and elements >100 bp in length or with conservation scores >75 within the 200-kb window centered on each index SNP. Outside of the targeted GWAS loci, we also included exons and conserved elements of MYC and PVT1 because of their potential importance in prostate cancer. We designed and ordered Agilent SureSelect 32 in-solution enrichment probes to target a total of 12 Mb in two rounds of target design. The total span of the regions we wished to target was 16.7 Mb, but we were not able to design probes for 4.7 Mb owing to the presence of repetitive elements that needed to be masked during probe design (Supplementary Table 1) .
We produced a total of 9,237 next-generation Illumina sequencing libraries from four ancestry groups (4,006 African, 1,753 European, 1,770 Japanese and 1,708 Latino) using a high-throughput library construction strategy previously described in ref. 33 (Online Methods). The results of the sequencing are presented in Table 1 , where information on the mean coverage and the total number of variants discovered is provided for each ancestry group. The total number of megabases targeted, the mean coverage, the number of sites discovered and other metrics for each region are provided in Supplementary Table 3 ). The coverage we obtained for the great majority of samples was high enough in theory to obtain reliable diploid genotype calls after imputation at most targeted bases 34 . To assess the accuracy of sequencing, we measured the Pearson correlation of these genotype calls with those made using arrays (roughly half of the samples had also been assayed using GWAS arrays). The correlation between the genotype calls from sequencing and arrays was r 2 = 0.84 before imputation, increasing to 0.92 after imputation (Supplementary Fig. 1 ).
Sequencing explains additional variance beyond GWAS SNPs
To explore the value of sequencing in explaining additional variance in prostate cancer risk, we fit the genetic data to variance-components models to estimate the contribution of all genetic variants at the sequenced risk loci to the underlying liability of prostate cancer. First, we used simulations starting from the real genotype data to quantify potential biases in variance-components estimation. Consistent with findings of previous studies 35 , our simulations show that the approach of using two variance components-one for rare variants (0.1% ≤ MAF < 1%) and one for common variants (MAF ≥ 1%)-estimated from dosage data and fitted jointly using restricted maximum likelihood (REML) as implemented in GCTA 36 produces the least amount of bias when estimating SNP heritability (Supplementary Figs. 2-9 and Supplementary Table 4). We also investigated the performance of fitting the REML equations with AI-REML, a Newton-style approach, versus an EM-based approach, EM-REML, as implemented in GCTA, with AI-REML attaining the least bias in our data ( Supplementary  Fig. 10 , Supplementary Tables 5 and 6, and Supplementary Note).
We considered the effect of estimating SNP heritability from best-guess calls rather than imputed dosages and found that these approaches give statistically indistinguishable results. Lastly, we explored the role of adjustment for LD in estimating the genetic relationship matrix (GRM) and observed upward bias for LD-adjusted GRMs when the underlying heritability explained by rare variants (hg,rare 2 ) was set to 0 in our simulations. This upward bias was also reflected in estimates made using real phenotype data (Supplementary Table 7) . Similar results were obtained over a variety of simulated disease architectures with various amounts of contribution from rare variation and total numbers of underlying causal variants (Supplementary Note).
Motivated by our simulation findings, we estimated the contribution of rare and common variation to risk of prostate cancer by fitting two variance components in GCTA while correcting for the top ten principal components and age; we report heritability estimates on the liability scale (Online Methods; see Supplementary  Fig. 11 for the principal-component analysis plot). We find that the total variance explained by all variants at these loci (SNP heritabil-
= + , , rare common ) is larger than what is explained by the index variants alone ( Table 2) . For example, we estimate the variance explained by all variants in the African-ancestry sample at 0.30 (s.e. = 0.06), which is significantly larger (P < 0.05) than the variance explained by all 84 index variants present in these data (0.06, s.e. = 0.01) (six of the 90 SNPs targeted were not covered by reads passing our analysis filters). This finding is consistent across all ancestry groups, thus emphasizing the usefulness of sequencing in recovering additional signal beyond index GWAS variants 37 . 
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Next, we searched for genetic heterogeneity by ancestry in prostate cancer risk using a bivariate REML analysis 38 . Briefly, we computed a single GRM for each unique pair of ancestry groups over the set of SNPs common to both ancestry groups (Online Methods) and estimated the genetic correlation using GCTA 36 . We then tested the hypotheses that there is no shared genetic liability (SNP r g = 0) and that liability is completely shared (SNP r g = 1) (Online Methods). We find significant heterogeneity (after accounting for the six pairs tested) for the African and European ancestry groups (SNP r g = 0.56, s.e. = 0.15; P value (SNP r g = 1) = 2.42 × 10 -3 ; Table 3 ) and nominally significant heterogeneity (P value = 0.04) for the Latino and African ancestry groups ( Table 3) .
Having established evidence of heterogeneity, we quantified the contribution to SNP heritability of variants across the MAF spectrum in each ancestry group independently. Rare variants explained a significant amount of SNP heritability (h g 2 ) in African-ancestry
rare 2 0 12 = , s.e. = 0.05; P = 2.29 × 10 -3 ); indeed, the heritability explained by these rare variants is comparable to the heritability explained by common variants at these loci (h g , . We did not observe significant contribution of rare variation to heritability in the other ancestry groups, although, given the limited sample sizes for the other groups, we cannot exclude the possibility that the fraction of prostate cancer heritability attributable to rare variants is the same in the other groups. In most of the analyses of heritability stratified by variant frequency that follow, we focus on people of African ancestry, as we had the highest power to carry out these studies.
We investigated whether the large contribution from rare variants in men of African ancestry was an artifact of data quality Tables 20 and 21; see Supplementary Tables 22-27 for results for other ancestry groups). To account for possible confounding from population substructure, we re-estimated the variance attributable to the rare frequency class in the African-ancestry sample, stratifying on the basis of Ugandan and non-Ugandan ancestry as well as the 8q24 locus, which is known to make a large contribution to risk of prostate cancer. Overall, we found no significant difference in h g ,rare 2 for the African-American subsets with and without the 8q24 region included in the estimation (Supplementary Table 28 ). We also considered bias in our initial estimates of h g 2 resulting from potential misspecification of the GRM. Specifically, we estimated variance components using non-standardized genotype data 35 (thereby reducing the impact of rare variants in GRM computation) and found a similar contribution from the rare variant spectrum (Online Methods). We also standardized the GRM on the basis of the expected variance rather than the sample estimate and found no significant The results for index SNPs correspond to h g 2 contributed solely from the targeted index variants. Estimates for h g 2 attributable to rare and common components were obtained from joint REML analysis on the underlying liability scale. Rare variants are defined as those with 0.1% ≤ MAF < 1%, whereas common variants are defined as those with MAF ≥ 1%. 
, s.e. = 0.05). We investigated potential bias in GCTA estimates from linkage across variants of various frequencies by repeating the analysis with three variance components corresponding to rare (0.1% ≤ MAF < 1%), low-frequency (1% ≤ MAF < 5%) and common (MAF ≥ 5%) variants; we observed no significant difference in the amount of variance attributable to the rare variant class (Supplementary value was set to 0 (all causal variants were set to have MAF ≥ 1%). In none of the 1,000 runs did we observe an estimate of h g ,rare 2 ≥ 0.12, giving an empirical P value <1/1,000. Finally, we performed variancecomponents analyses using genotypes obtained from best-guess calls, as well as standard unconstrained REML analyses. Overall, we found that most of these potential sources of bias are unlikely to significantly change our results (Supplementary Figs. 2-9, Supplementary  Tables 32-35 and Supplementary Note).
Evidence of coupling between selection and allelic effects
In the case of neutral genetic variation, alleles that have a MAF <1% account for only a few percent of genetic variation in the population. However, our empirical results from this study show that, at loci known to harbor common variants conferring risk for prostate cancer, variants with MAF < 1% account for an order of magnitude larger heritability for the disease. The only plausible explanation for this observation is that newly arising mutations that confer risk for prostate cancer-especially mutations of strong effect-are often subject to selection that is strong enough to prevent them from becoming common.
To quantify the extent to which selection is driving down the frequency of alleles that confer risk for prostate cancer, we derived a simulation-based pipeline that uses estimates of h g ,rare 2 to constrain the value of a parameter τ that Eyre-Walker proposed to measure the coupling between selection coefficients and allelic effect sizes 39 (Online Methods). Briefly, starting from the real genotype data, we simulated phenotypes under Eyre-Walker's model at various values of τ and estimated h g ,rare 2 in the simulated trait. We then compared the observed heritability in the real data to the simulations while accounting for sampling noise (Online Methods). We estimated τ = 0.48 with a 95% confidence interval of [0.19, 0.78] for the African-ancestry sample under our mapping procedure (Fig. 1) . We obtained similar results using a MAF cutoff of 5% in assigning variants to the rare versus common class (Supplementary Fig. 13 ). We found that our procedure was relatively robust to changes in parameters. For example, when adjusting the effective population size for African ancestry to 7,500, we re-estimated τ = 0.46 with a 95% confidence interval of Table 36 ). Although the small contribution from rare variants together with small sample sizes for the European, Japanese and Latino data sets prohibits us from estimating a tight confidence interval for Eyre-Walker's τ in these populations, the results were roughly consistent across populations ( Table 4 and Supplementary Fig. 14) . For example, the estimated mean value of τ for the Japanese cohort was 0.38 with a 95% confidence interval of [-0.07, 0.32]. In a meta-analysis over all ancestry groups, we estimated τ = 0.42 [0.22, 0.62], which is similar to the African-ancestry estimates (unsurprisingly, as the African-ancestry data contribute the most to this analysis).
Single-variant association
An advantage of sequencing data-even with a tenfold lower sample size in comparison to the largest current GWAS-is that it interrogates all variants in the analyzed samples and thus has the potential to detect causal variants that are not genotyped or imputed in GWAS. We performed marginal association testing at all sequenced variants (n = 197,786) and replicated most of the GWAS-identified loci (Supplementary Tables 37-42 ). We observed a marginal increase in the association signal when including rare variants with 0.1% ≤MAF < 1% across all populations, as reflected in a decrease in the top -log 10 (P value) (Supplementary Tables 37-42 ) and a slight enrichment of low P values in a burden test ( Supplementary  Fig. 15 ). However, a limitation of the present study is its modest sample size in comparison to the sample size of 87,040 individuals in the most recent GWAS meta-analyses 24 . For example, of the 84 recovered index variants (six of the 90 targeted SNPs were not covered by reads passing our analysis filters), only seven had a P value <1 × 10 −8 (most at 8q24) and only 13 had a P value <1 × 10 −4 . Thus, even though we can directly access alleles not on SNP arrays through our targeted sequencing, the advantage we obtain by directly genotyping SNPs is more than counterbalanced by the tenfold larger GWAS meta-analysis that has conducted imputation for fine mapping of common alleles at these regions. To explore additional signal beyond the known index Meta-analysis results were computed using an inverse-weighted variance approach. Similar results were obtained with MAF partitioning at 5% (supplementary Fig. 13 ).
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A r t i c l e s variants, we performed a conditioning analysis (Online Methods) on the index variants and observed no variants with P value <1 × 10 −8 after conditioning; quantile-quantile plots showed residual signal only in the African-ancestry sample, consistent with the hypothesis that there is an additional signal beyond that contributed by the known variants at these loci (either due to better tagging of a single causal variant or the presence of multiple causal alleles 37 ) (Supplementary Figs. 16-18) .
To investigate sequenced SNPs as plausible causal alleles, we integrated epigenetic and genetic data using PAINTOR 40 to estimate posterior probabilities for causality at each SNP. We used the metaanalysis results for SNPs with MAF ≥ 1.0% (as the Wald statistic is unreliable at MAF < 1% and therefore not well suited to estimation within the PAINTOR framework). First, we ran PAINTOR independently for each of the 20 functional categories that have previously been implicated in prostate cancer 41 and found a significant enrichment for causal variants in FOXA1-binding sites assayed in the LNCaP cell lines as well as at binding sites for androgen receptor 41 (Supplementary Fig. 19 ). Second, we selected the functional categories with significant enrichment (at a nominal level of P ≤ 0.05) for a joint PAINTOR model to estimate posterior probabilities that each SNP is causal. Of the 24,840 common variants found in all ancestry groups, we identified nine variants with PAINTOR posterior probability >0.90 as causal. In particular, two variants (rs78416326 and rs10486567) exhibited posterior probabilities >0.99 owing to a combination of strong association signal and overlap with functional elements (Supplementary Fig. 20 and Supplementary  Table 43 ). Although biological causality cannot be proven on the basis of statistical association alone, we highlight the variants with high posterior probability for follow-up validation.
DISCUSSION
We have used large-scale targeted sequencing to study the contribution of rare variants to the heritability of prostate cancer for individuals of diverse ancestry. We find that the total variance in the trait contributed by these regions is significantly greater than the variance localized to known GWAS variants, thus showing that large-scale sequencing can uncover missing heritability. We also provide evidence of heterogeneity by ancestry as well as the first direct evidence of which we are aware of rare variants contributing a disproportionate fraction of the genetic heritability for a common disease. On first principles, there are reasons to think that our results actually underestimate the fraction of heritability due to rare variants. First, our study does not have a sample size sufficient to interrogate extremely rare variants (frequency << 0.1%). Second, we focused on known GWASidentified regions that were ascertained on the basis of harboring an association with a common variant, thus guaranteeing that common variants would be responsible for a substantial fraction of prostate cancer risk at these locations.
Our finding that 42% (95% confidence interval = 21-63%) of the genetic risk for prostate cancer is due to variants in the MAF range of 0.1-1% is striking, given that only a couple percent of neutral variation is due to SNPs in this frequency range. These results suggest that selection has placed downward pressure on the frequencies of many alleles contributing risk for prostate cancer, and we have quantified this coupling of selection and prostate cancer risk. Prostate cancer is a late-onset disease that primarily affects people after reproductive age. For diseases with younger onset, it is plausible that the coupling of selection to disease risk could be even higher, and we predict that this will be observed for other diseases when sequencing studies of large sample size are performed and analyzed using methods like the ones we report here that are capable of partitioning heritability by frequency 42 . Already, associations with rare variants have been found at both the gene and individual-SNP levels [43] [44] [45] as well as through sequencing of known GWAS risk loci 46 . Because we have shown that rare variation is capable of explaining a substantial portion of SNP heritability for prostate cancer, we expect that it will be useful to incorporate rare variants into statistical models for prediction of disease risk. Taken together, these results motivate further large sequencing efforts in diverse populations to fully explore the abundance of rare variants that might contribute a substantial fraction of the heritability for at least some important human phenotypes.
We conclude with several caveats. Although we genotyped the majority of variants at the risk-associated regions in the regions we targeted in sequencing, we were not able to sequence a subset of the regions owing to the fact that the technology we used could not enrich for sequences at repetitive regions. Second, the part of the genome we analyzed in this study is non-random: we analyzed loci discovered by common variant association methods, where the fraction of genetic heritability due to common variants is likely to be overestimated owing to the fact that the regions were discovered on account of containing common variants. Thus, it is plausible that the true fraction of heritability for prostate cancer that is due to rare variants is a conservative underestimate of the true proportion across the genome. Third, assaying SNP heritability using variance components makes a number of simplifying assumptions; although we could not identify any source of bias that could explain our results artifactually, it is important to recognize that the analyses we have performed are statistically complex and there might be biases we have not appreciated. An important direction for future work will be to carry out whole-genome sequencing studies in much larger sample sizes, which will provide sufficient statistical power to allow a direct SNP-by-SNP understanding of the contribution of variants in the MAF range of 0.1-1% that this study suggests make a major contribution to human genetic risk for prostate cancer.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The data reported in this study are available at the database of Genotypes and Phenotypes (dbGaP) under accession phs000306.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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This work is supported in part by the US National Institutes of Health (R01 CA165862, U19 CA148537, UM1 CA164973, RC2 CA148085, U01 CA1326792, R21 CA182821 and U01 CA188392). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. that is, the proportion of total SNP heritability explained by rare SNPs. The SNP heritability analysis was performed on the dichotomous case-control phenotype using constrained REML in GCTA with a prevalence of 0.19 for the African-ancestry group, 0.14 for the European-and Latino groups, and 0.10 for Japanese (SEER; see URLs). Hence, all reported values of h g 2 are on the underlying liability scale. To estimate the contribution of the known index variants to SNP heritability, we computed a GRM restricted to the 84 known variants. The covariate matrix for each ancestry group consisted of age and the first ten principal components (with an additional binary variable indicating Ugandan ancestry for the African-ancestry group). LD-adjusted GRMs were computed using LDAK 56 version 4.2. P values were estimated from a likelihood-ratio test by dropping one component and comparing against the reduced model (as implemented in GCTA). To estimate GRMs from array data, we removed any SNP within 0.5 Mb of the targeted regions and further pruned for pairwise LD >0.2 in addition to any remaining variants in LD with index SNPs (Supplementary Fig. 22 ). For bivariate REML analysis, we define the GRM for samples over two ancestry groups as where Z i is the standardized genotype matrix for ancestry group i and m is the number of SNPs shared by both groups 57 .
Coupling selection with allelic effect size. We investigated the relationship between selection and marginal effect sizes on prostate cancer risk using the Eyre-Walker model 39 , which sets allelic effect sizes b t = ( ) + ( )
Here N e is the effective population size (set to 10,000 for our analyses 58 ), s is the selection coefficient of the allele and ε is normally distributed noise (σ ε = 0 5
. ; varying this parameter does not significantly affect underlying rare/common variation 39 ). As τ increases, we expect the allelic effects and, thus, the contribution to h g 2 from rare variants, to increase as a result of rare SNPs experiencing stronger selective pressure than common SNPs (Supplementary Figs. 22-24) .
To determine how τ has a possible role in the underlying architecture for prostate cancer, we followed a five-step simulation procedure: (i) we randomly select a set of 10,000 SNPs to be causal; (ii) we assign selection coefficients to each causal variant by mapping their allele frequency to selection coefficients 59 ; (iii) we simulate allelic effects under the Eyre-Walker model given selection coefficients, τ and s ε = 0 5 . ; (iv) we simulate a continuous trait starting from the real genotype data with total SNP heritability matching the SNP heritability estimated from real data; and (v) we perform joint REML analysis in GCTA to estimate rare and common SNP heritability for the simulated trait. We repeated this procedure for 5,000 values of τ uniformly distributed over the interval [- and identified the closest estimate observed from the simulation pipeline and recorded its simulated value for τ. This enabled us to convert the statistical noise around the estimate of the proportion as obtained by GCTA into a variance around τ for each of the ancestry samples.
